Temozolomide, used frequently in the adult setting for its favorable toxicity profile, has a clear risk of hypermutation whilst IDH inhibitors have not been tested in the pediatric CNS tumor population and need further study to determine impact on tumor biology and efficacy at recurrence. The gene discussed is IDH2; the disease is central nervous system neoplasm.